📰 Adjunct Therapy News
Page 2 - Adjunct Therapy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adjunct Therapy. Real-time updates on events, politics, business and more.
February 16, 2024
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young...
February 16, 2024
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as...
February 16, 2024
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate...
January 30, 2024
A study on the effects of using omalizumab, in the treatment of food allergies, has shown an improved tolerance to a variety of everyday foods in children and adolescents.
December 19, 2023
– If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure – – Interim analysis results from first-of-its-kind Phase III...
December 19, 2023
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...
October 30, 2023
Tongxinluo, a compound made from extracts of plants and insects, has been in use in Chinese medicine for treating heart attacks.
October 9, 2023
/PRNewswire/ -- Bleeding disorders are typically hereditary, with common symptoms encompassing easy bruising, frequent nosebleeds, heavy menstrual bleeding,...
June 1, 2021
New Delhi [India], June 1 (ANI): The Defence Research and Development Organisation's (DRDO) on Tuesday said that the anti-COVID drug 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings.
June 1, 2021
Pic credit: ANI NEW DELHI: The Defence Research and Development Organisations (DRDO) on Tuesday said that the anti-Covid drug 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings. The DRDO said that anti-Covid drug 2DG can now be given to Covid 19 patients under the care and prescription of doctors. DRDO also issued some important guidelines with regard to its anti-Covid -19 drug. "Ideally, 2DG shoul...